Table 1 |
||||||
|
Demographic features of patients and controls |
||||||
|
RA-TNF1 (n = 38) |
RA-TNF2 (n = 38) |
TNF-naive RA (n = 40) |
TB (n = 30) |
Leprosy (n = 23) |
Healthy controls (n = 41) |
|
|
|
||||||
|
F:M |
31:7 |
31:7 |
29:11 |
21:9 |
7:16 |
29:12 |
|
|
||||||
|
Mean age (years) |
51.7 ± 14.2 |
51.7 ± 14.2 |
52.6 ± 13.5 |
43.0 ± 13.4 |
57.1 ± 9.6 |
41.1 ± 12.1 |
|
|
||||||
|
BCG scar (+) |
24 |
24 |
25 |
23 |
16 |
27 |
|
|
||||||
|
QTF |
||||||
|
|
||||||
|
(+) |
13 (34%) |
16 (42%) |
20 (50%) |
15 (50%) |
14 (61%) |
19 (47%) |
|
|
||||||
|
(-) |
23 (61%) |
22 (58%) |
19 (47%) |
13 (43%) |
8 (35%) |
22 (53%) |
|
|
||||||
|
Indeterminate |
2 (5%) |
0 |
1 (3%) |
2 (7%) |
1 (4%) |
0 |
|
|
||||||
|
TST |
||||||
|
|
||||||
|
10 mm (+) |
9 (24%) |
14 (37%) |
22 (55%) |
17 (57%) |
13 (57%) |
28 (68%) |
|
|
||||||
|
5 mm (+) |
10 (26%) |
17 (45%) |
24 (60%) |
21 (70%) |
14 (61%) |
33 (80%) |
|
|
||||||
|
Results in rheumatoid arthritis patients before (RA-TNF1) and after (RA-TNF2) treatment with TNF-α antagonists, rheumatoid arthritis patients who were not prescribed TNF-α antagonists (TNF-naive RA), rheumatology patients who had current or past confirmed tuberculosis infection (TB), leprosy patients, and healthy controls. |
||||||
|
Hatemi et al. Arthritis Research & Therapy 2012 14:R147 doi:10.1186/ar3882 |
||||||
